Quanterix Corporation announced it signed a new license agreement with bioMérieux, to provide expanded flexibility for both parties to commercialize products within their respective fields. Under this new agreement, Quanterix will have broader licensing rights within the IVD protein field, therefore both companies will have the ability to develop instruments for commercialization in the IVD space. Quanterix can further license its Simoa technology, as well as go-to-market directly with a new Point-of-Care device or Lab Developed Test. Widespread access to Simoa’s superior sensitivity and fully automated capabilities will provide researchers with the ability to quickly and more accurately detect injury and disease, improving treatment and prognoses in the future. Within the frame of this agreement, bioMérieux retains the rights to develop the technology focusing on its strategic priorities. The terms of this agreement incorporates a one-time milestone payment in addition to royalties based on commercial sales.